Skip to content
2000
Volume 15, Issue 3
  • ISSN: 1566-5232
  • E-ISSN: 1875-5631

Abstract

The genetic engineering of T cells can lead to enhanced immune-mediated tumour destruction and harbors a great potential for the treatment of cancer. Recent efforts have centered on the design of receptors to re-direct the specificity of T cells towards tumour antigens by means of viral gene transfer. This strategy has shown great success in a number of phase one clinical trials. However, there are still challenges to overcome. On the one hand, T cell function can be further improved to optimize the therapeutic outcome. On the other hand, so called safety switches are required to deal with possible on and off target toxicities. In this review, we will give a brief summary of the success and risks of T cell gene therapy before discussing in detail current strategies to enhance effector function, persistence and safety of adoptively transferred T cells.

Loading

Article metrics loading...

/content/journals/cgt/10.2174/1566523215666150126123037
2015-06-01
2025-04-23
Loading full text...

Full text loading...

/content/journals/cgt/10.2174/1566523215666150126123037
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test